BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32226300)

  • 1. Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
    Xiang M; Jiang HG; Shu Y; Chen YJ; Jin J; Zhu YM; Li MY; Wu JN; Li J
    Int J Biol Sci; 2020; 16(9):1536-1550. PubMed ID: 32226300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
    Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
    Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis.
    Chen P; Dai CH; Shi ZH; Wang Y; Wu JN; Chen K; Su JY; Li J
    Apoptosis; 2021 Dec; 26(11-12):639-656. PubMed ID: 34743246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
    Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
    Liu T; Jin L; Lu W; Gan H; Lin Z; Chen M; Liu J; Zhang F; Wang S; Zhang H; Deng W; Chen H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):148. PubMed ID: 30953548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
    Zhang Z; Lian X; Xie W; Quan J; Liao M; Wu Y; Yang ZZ; Wang G
    Sci Rep; 2020 Dec; 10(1):20924. PubMed ID: 33262410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
    J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy.
    Wang XJ; Zhou RJ; Zhang N; Jing Z
    Eur J Pharmacol; 2019 May; 850():141-149. PubMed ID: 30772396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
    Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R
    Medicine (Baltimore); 2017 Aug; 96(33):e7732. PubMed ID: 28816950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis.
    Dai CH; Zhu LR; Wang Y; Tang XP; Du YJ; Chen YC; Li J
    J Cell Physiol; 2021 Jun; 236(6):4538-4554. PubMed ID: 33230821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
    Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X
    Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.